University of North Carolina Chapel Hill Physician Office Building
Welcome,         Profile    Billing    Logout  
 1 Trial 
9 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Grilley-Olson, Juneko
ARGSARC, NCT05712694: Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects with Leiomyosarcoma

Recruiting
3
300
Canada, US, RoW
ADI PEG20, Pegargiminase, Placebo
Polaris Group
Soft Tissue Sarcoma
12/27
12/27
SUNRISELMS, NCT05269355 / 2022-000073-12: A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

Active, not recruiting
2/3
360
Europe, Canada, US, RoW
Unesbulin, PTC596, Dacarbazine, DTIC, Placebo
PTC Therapeutics, PTC Therapeutics, Inc.
Leiomyosarcoma
06/24
06/24
Frigault, Matthew J
NCT06550141: Emapalumab Prevention of CAR-T Cell Associated Toxicities

Recruiting
2
28
US
Emapalumab, Human anti-interferon gamma (IFNγ) monoclonal antibody, Gamifant, Cyclophosphamide, Fludarabine Phosphate, Axicabtagene Ciloleucel
Marcela V. Maus, M.D.,Ph.D., Swedish Orphan Biovitrum
Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
08/26
08/27
NCT05952804: IVIG for Infection Prevention After CAR-T-Cell Therapy

Recruiting
2
150
US
Immune Globulin Infusion (Human), 10% Solution, GAMMAGARD LIQUID, Anti-CD19 CAR T Cells Preparation, CD19-targeting CAR-T Cells, Saline, 7647-14-5, ISOTONIC SODIUM CHLORIDE SOLUTION, Sodium Chloride 0.9%, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Survey Administration, Electronic Health Record Review
Fred Hutchinson Cancer Center, Takeda, National Cancer Institute (NCI)
Lymphoma
07/27
07/28
NCT05296525: Evaluation of Safety and Efficacy of Allo GDA-201 NK Cells in Patients With Relapsed/Refractory B Cell NHL

Terminated
1/2
13
US
GDA-201, NAM NK
Gamida Cell ltd
Non-Hodgkin Lymphoma
04/24
04/24
CYTB323A12101, NCT03960840: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Recruiting
1/2
225
Europe, Japan, US, RoW
Rapcabtagene autoleucel single agent, Ibrutinib
Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
06/27
05/28
NCT04134117: Tisagenlecleucel in Primary CNS Lymphoma

Completed
1
6
US
Tisagenlecleucel, KYMRIAH
Matthew J. Frigault, M.D., Novartis
Primary CNS Lymphoma, Refractory Primary CNS Lymphoma, Relapsed Primary CNS Lymphoma
04/22
04/22
ARC-101, NCT04155749: Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Active, not recruiting
1
40
US
anitocabtagene-autoleucel
Kite, A Gilead Company, Arcellx, Inc.
Relapsed and Refractory Multiple Myeloma
08/24
11/35
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 

Download Options